Sentiment Survey
|
|
|
|
|
|
|
|
|
|
|
|
Investment Grade:
|
|
Comments(0)
|
(0)
|
(0)
|
Ranking History
Headlines
- New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
May 29, 2008 08:59 AM
- New England Journal of Medicine Publishes Results From a RELISTOR Phase 3 Clinical Study
May 29, 2008 08:59 AM
- Bulls Hope For Oil Top
May 22, 2008 09:52 AM
- Wyeth/Progenics Drug Doesn't Meet Endpoints In Phase III
May 22, 2008 07:43 AM
- Media Digest for 4/25
Apr 25, 2008 10:07 AM
- NASDAQ Technical Picture - Resistance Overhead
Apr 07, 2008 01:01 AM
- April Fools Day
Apr 01, 2008 09:57 AM
- Awaiting Paulson
Mar 13, 2008 10:38 AM
- Hump Day
Mar 12, 2008 10:20 AM
- Market Analysis for 3/12
Mar 12, 2008 10:17 AM
- Wyeth and Progenics Announce Positive Outcome of Phase 3 Clinical Study of Subcutaneous RELISTOR for Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain
Nov 26, 2008 08:07 AM
- Progenics Announces Wyeth Has Received RELISTOR Approval in Australia
Nov 17, 2008 08:10 AM
- Progenics Reports Third Quarter 2008 Financial Results and Corporate Updates
Nov 10, 2008 08:13 AM
- Progenics Selects Small-Molecule Hepatitis C Drug Candidate for Clinical Development
Nov 04, 2008 08:08 AM
- Progenics Reports Positive Interim Phase 2 Results for Two Dosage Forms of Novel HIV Therapy PRO 140
Oct 26, 2008 12:16 PM
- Progenics Pharmaceuticals and Ono Pharmaceutical Announce Agreement to Develop and Commercialize RELISTOR in Japan
Oct 16, 2008 07:46 PM
- Progenics Announces Progress and Presentations in HIV Therapy Program
Oct 02, 2008 08:10 AM
- Progenics Initiates Phase 1 Clinical Study of Targeted Therapy for Prostate Cancer
Sep 08, 2008 07:12 AM
- Progenics Pharmaceuticals Reports Second Quarter 2008 Results
Aug 08, 2008 07:01 AM
- Wyeth and Progenics Receive Approval from European Commission for RELISTOR for Opioid-Induced Constipation in Advanced Illness Patients
Jul 03, 2008 12:58 PM
- Form 4 JACOBSON PAUL F For: Oct 22 (10K)
Oct 24, 2008 06:01 PM
- Form 4 PROGENICS PHARMACEUTICAL For: Oct 01 Filed by: Boyd Thomas A (10K)
Oct 03, 2008 01:34 PM
- Form 4 PROGENICS PHARMACEUTICAL For: Oct 01 Filed by: Olson William C (10K)
Oct 03, 2008 01:33 PM
- Form 4 PROGENICS PHARMACEUTICAL For: Oct 01 Filed by: MCKINNEY ROBERT A (10K)
Oct 03, 2008 01:33 PM
- Form 4 PROGENICS PHARMACEUTICAL For: Oct 01 Filed by: ISRAEL ROBERT J (10K)
Oct 03, 2008 01:33 PM
- Form 4 PROGENICS PHARMACEUTICAL For: Oct 01 Filed by: Baker Mark Robert (10K)
Oct 03, 2008 01:29 PM
- Form 4 PROGENICS PHARMACEUTICAL For: Sep 03 Filed by: ISRAEL ROBERT J (10K)
Sep 04, 2008 11:45 AM
- Form 4 BRINER KURT W For: Aug 28 (10K)
Aug 29, 2008 12:14 PM
- Form 4 PROGENICS PHARMACEUTICAL For: Aug 01 Filed by: ISRAEL ROBERT J (10K)
Aug 05, 2008 10:08 AM
- Form 4 PROGENICS PHARMACEUTICAL For: Jul 15 Filed by: JACOBSON PAUL F (10K)
Jul 17, 2008 02:08 PM
Analyst Ratings
|
|
Share Performance
|
Period
|
PGNX
|
Compare to S&P
|
| YTD |
-48.70 %
|
-15.95 %
|
| 4 Weeks |
-7.39 %
|
0.10 %
|
| 12 Weeks |
-34.53 %
|
-9.26 %
|
|
Financial Ratios
Earnings Performance
|
EPS Growth in Last Quarter: -412.50 %
|
|
EPS Growth in Last Year: 29.31 %
|
|
Sales Growth in Last Quarter: -38.79 %
|
|
Sales Growth in Last Quarter: 2.81 %
|
|
|
